David W. Meyer

1.3k total citations
16 papers, 776 citations indexed

About

David W. Meyer is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, David W. Meyer has authored 16 papers receiving a total of 776 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Molecular Biology. Recurrent topics in David W. Meyer's work include HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Cancer therapeutics and mechanisms (2 papers). David W. Meyer is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Cancer therapeutics and mechanisms (2 papers). David W. Meyer collaborates with scholars based in United States and Germany. David W. Meyer's co-authors include Peter D. Senter, Martha E. Anderson, Jamie B. Miyamoto, Jonathan M. Scholey, Douglas G. Cole, Dana J. Rashid, Karen P. Wedaman, Patrick Burke, Scott C. Jeffrey and Robert P. Lyon and has published in prestigious journals such as The Journal of Cell Biology, Blood and Cancer Research.

In The Last Decade

David W. Meyer

16 papers receiving 738 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David W. Meyer United States 9 437 363 332 119 106 16 776
Chisato M. Yamazaki Japan 12 528 1.2× 452 1.2× 399 1.2× 46 0.4× 33 0.3× 16 1.1k
Lydia Armstrong United States 12 299 0.7× 600 1.7× 75 0.2× 156 1.3× 95 0.9× 19 872
Maureen Dougher United States 14 587 1.3× 345 1.0× 433 1.3× 38 0.3× 94 0.9× 24 1.0k
Olivier Zwaenepoel Belgium 15 115 0.3× 410 1.1× 250 0.8× 104 0.9× 27 0.3× 28 620
Mattia Matasci Switzerland 18 218 0.5× 602 1.7× 222 0.7× 72 0.6× 21 0.2× 37 913
Ranjan Maity Canada 15 498 1.1× 1.0k 2.8× 98 0.3× 52 0.4× 254 2.4× 41 1.3k
Yang Feng United States 16 307 0.7× 549 1.5× 196 0.6× 254 2.1× 12 0.1× 26 859
Lori Westendorf United States 14 728 1.7× 522 1.4× 646 1.9× 17 0.1× 142 1.3× 29 1.2k
J. Gutheil United States 5 254 0.6× 372 1.0× 133 0.4× 38 0.3× 31 0.3× 12 630
Beatrice Langton-Webster United States 16 749 1.7× 521 1.4× 504 1.5× 70 0.6× 12 0.1× 27 1.2k

Countries citing papers authored by David W. Meyer

Since Specialization
Citations

This map shows the geographic impact of David W. Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David W. Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David W. Meyer more than expected).

Fields of papers citing papers by David W. Meyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David W. Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David W. Meyer. The network helps show where David W. Meyer may publish in the future.

Co-authorship network of co-authors of David W. Meyer

This figure shows the co-authorship network connecting the top 25 collaborators of David W. Meyer. A scholar is included among the top collaborators of David W. Meyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David W. Meyer. David W. Meyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Meyer, David W., Sara Shum, Mechthild Jonas, et al.. (2020). An in Vitro Assay Using Cultured Kupffer Cells Can Predict the Impact of Drug Conjugation on in Vivo Antibody Pharmacokinetics. Molecular Pharmaceutics. 17(3). 802–809. 23 indexed citations
2.
Emmerton, Kim K., Nicole M. Okeley, Jessica K. Simmons, et al.. (2020). Abstract 2885: Discovery of a tripeptide-based camptothecin drug-linker for antibody-drug conjugates with potent antitumor activity and a broad therapeutic window. Cancer Research. 80(16_Supplement). 2885–2885. 1 indexed citations
3.
Ryan, Maureen C., David W. Meyer, Jessica K. Simmons, et al.. (2020). Abstract 2889: SGN-CD30C, a new CD30-directed camptothecin antibody-drug conjugate (ADC), shows strong anti-tumor activity and superior tolerability in preclinical studies. Cancer Research. 80(16_Supplement). 2889–2889. 2 indexed citations
4.
Neumann, Christopher S., Martha E. Anderson, Julia H. Cochran, et al.. (2018). Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 17(12). 2633–2642. 32 indexed citations
5.
Sussman, Django, Lori Westendorf, David W. Meyer, et al.. (2018). Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability. Protein Engineering Design and Selection. 31(2). 47–54. 47 indexed citations
6.
Kluth, Martina, David W. Meyer, Antje Krohn, et al.. (2015). Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer. Oncotarget. 7(4). 3897–3904. 6 indexed citations
7.
Zong, Chenggong, Peipei Ping, Edward Lau, et al.. (2014). Lysine ubiquitination and acetylation of human cardiac 20S proteasomes. PROTEOMICS - CLINICAL APPLICATIONS. 8(7-8). 590–594. 12 indexed citations
8.
Burke, Patrick, Joshua H. Hunter, Scott C. Jeffrey, et al.. (2014). Abstract 1786: Development and pharmacological properties of PEGylated glucuronide-auristatin linkers. Cancer Research. 74(19_Supplement). 1786–1786. 1 indexed citations
9.
Sutherland, May S.K., Roland B. Walter, Scott C. Jeffrey, et al.. (2013). SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 122(8). 1455–1463. 291 indexed citations
10.
Jeffrey, Scott C., Patrick Burke, David W. Meyer, et al.. (2012). Abstract 4631: Anti-CD70 antibody-drug conjugates containing pyrrolobenzodiazepine dimers demonstrate robust antitumor activity. Cancer Research. 72(8_Supplement). 4631–4631. 1 indexed citations
11.
Sussman, Django, Lori Westendorf, David W. Meyer, et al.. (2012). Abstract 4634: Engineered cysteine drug conjugates show potency and improved safety. Cancer Research. 72(8_Supplement). 4634–4634. 2 indexed citations
12.
Burke, Patrick, Brian E. Toki, David W. Meyer, et al.. (2009). Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system. Bioorganic & Medicinal Chemistry Letters. 19(10). 2650–2653. 20 indexed citations
13.
Burke, Patrick, Peter D. Senter, David W. Meyer, et al.. (2009). Design, Synthesis, and Biological Evaluation of Antibody−Drug Conjugates Comprised of Potent Camptothecin Analogues. Bioconjugate Chemistry. 20(6). 1242–1250. 76 indexed citations
14.
Doronina, Svetlana O., Tim D. Bovee, David W. Meyer, et al.. (2008). Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate. Bioconjugate Chemistry. 19(10). 1960–1963. 133 indexed citations
15.
Meyer, David W., Daniel R. Rines, Anna Kashina, Douglas G. Cole, & Jonathan M. Scholey. (1998). [13] Purification of novel kinesins from embryonic systems. Methods in enzymology on CD-ROM/Methods in enzymology. 298. 133–154. 5 indexed citations
16.
Wedaman, Karen P., David W. Meyer, Dana J. Rashid, Douglas G. Cole, & Jonathan M. Scholey. (1996). Sequence and submolecular localization of the 115-kD accessory subunit of the heterotrimeric kinesin-II (KRP85/95) complex.. The Journal of Cell Biology. 132(3). 371–380. 124 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chisato M. Yamazaki Breakdown of academic impact, for papers by Lydia Armstrong Breakdown of academic impact, for papers by Maureen Dougher Breakdown of academic impact, for papers by Olivier Zwaenepoel Breakdown of academic impact, for papers by Mattia Matasci Breakdown of academic impact, for papers by Ranjan Maity Breakdown of academic impact, for papers by Yang Feng Breakdown of academic impact, for papers by Lori Westendorf Breakdown of academic impact, for papers by J. Gutheil Breakdown of academic impact, for papers by Beatrice Langton-Webster
Rankless by CCL
2026